Brief: Lansen Pharmaceutical Holdings Says Unit to Buy Stake in Tianjin Robustnique Biotechnology
31/12/2018 05:11
Dec 31 (Reuters) - Lansen Pharmaceutical Holdings Ltd
0503.HK :
* LANSEN PHARMACEUTICAL HOLDINGS LTD ANNOUNCES PURCHASE OF
EQUITY
INTEREST IN ROBUSTNIQUE
* UNIT TO PURCHASE 20% EQUITY INTEREST IN TIANJIN
ROBUSTNIQUE
BIOTECHNOLOGY FOR RMB14 MILLION
Source text for Eikon: urn:newsml:reuters.com:*:nHKS7BLBZZ
Further company coverage: 0503.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lansen Pharmaceutical Holdings
See all newsBrief: Lansen Pharmaceutical Says Stock Exchange Approved Withdrawal Of Listing Of Shares From 9 AM, 19 Dec
Brief: Lansen Pharmaceutical Updates Withdrawal Of Listing Of Shares On Stock Exchange
Brief: Lansen Pharmaceutical Says Trading In Shares Will Be Halted
Brief: Lansen Pharmaceutical Posts FY Revenue Of $65.6 Mln VS $54.2 Mln
Brief: Lansen Pharmaceutical Sees Net Profit Attributable Of Approximately $8.1 Million For Year